Immune Related Adverse Events Associated with Checkpoint Inhibition in the Setting of CAR T-Cell Therapy: A Case Series

ConclusionsT cell exhaustion has been suspected to contribute to poor persistence of CAR T-cells and clinical relapse, which may be overcome by checkpoint inhibition. While the synergy between CAR T-cell therapy and checkpoint inhibition is promising, the interaction may also lead to off-target irAEs. Prospective trials exploring the safety and efficacy of this combination in relapsed/refractory DLBCL are under way.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research